Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain

INTRODUCTION: Clostridium difficile infection (CDI) is the major cause of infectious nosocomial diarrhoea and is associated with considerable morbidity, mortality and economic impact. Bezlotoxumab administered in combination with standard of care (SoC) antibiotic therapy prevents recurrent CDI. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Salavert, Miguel, Cobo, Javier, Pascual, Álvaro, Aragón, Belén, Maratia, Stefano, Jiang, Yiling, Aceituno, Susana, Grau, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223985/
https://www.ncbi.nlm.nih.gov/pubmed/30328061
http://dx.doi.org/10.1007/s12325-018-0813-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223985/
https://www.ncbi.nlm.nih.gov/pubmed/30328061
http://dx.doi.org/10.1007/s12325-018-0813-y

Ejemplares similares